Lovisa Afzelius, Apriori Bio CEO

Flag­ship un­wraps new AI biotech that looks to pre­dict vari­ants be­fore they’re here

While Mod­er­na is test­ing Omi­cron-spe­cif­ic boost­ers for this fall, its in­vestor Flag­ship Pi­o­neer­ing is build­ing a biotech that says it us­es AI to pre­dict virus vari­ants pri­or to out­breaks.

Apri­ori Bio, de­rived from the Latin phrase a pri­ori that trans­lates to “from the pre­vi­ous,” emerged from stealth Mon­day with $50 mil­lion. The Cam­bridge, MA-based biotech was found­ed in 2020 in the midst of the Covid-19 pan­dem­ic, though Apri­ori CEO Lo­visa Afzelius says the biotech will tack­le mul­ti­ple “ul­tra-dy­nam­ic” virus­es out­side of SARS-CoV-2, in­clud­ing the flu virus and HIV.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.